Latest Advances in Lung Cancer Research

FDA grants Fast Track status to ABD-147, a new lung cancer treatment. This antibody-drug conjugate, developed by AltruBio, could offer hope for ES-SCLC patients with limited options.

A University of Illinois Chicago study finds a correlation between living in violent neighborhoods and an increased risk of cancer.

China approves Tagrisso combined with chemotherapy as a new first-line treatment option for patients with EGFR-mutated advanced lung cancer.

Imfinzi shows promise in extending survival for patients with extensive-stage small cell lung cancer.

Japan approves Tagrisso with chemotherapy as a new first-line treatment for EGFR-mutated advanced lung cancer.

Lung cancer in never-smokers may respond poorly to immunotherapy due to genetic mutations, suggesting a need for tailored treatments.

Lung cancer screening significantly increases early detection and survival rates for at-risk US veterans, a new study finds.

Immunotherapy and chemotherapy before surgery show promise for stage 3 NSCLC patients, with 77% achieving two-year progression-free survival.

Dato-DXd shows promise in treating advanced “HER2-low” lung cancer, slowing progression and potentially extending survival.

Stepped palliative care for advanced lung cancer improves quality of life by integrating symptom management and emotional support earlier.

Osimertinib significantly extends progression-free survival in stage III EGFR-mutant lung cancer patients. The drug shows promise as a new standard treatment after chemo and radiation, with manageable side effects.

New treatments for lung cancer, including targeted therapies and immunotherapy, are extending lives and offering hope for patients.